What is pulmonary blastoma?
Pulmonary blastoma is a very rare lung cancer that mainly affects adults. Its name comes from its appearance: under the microscope, the tumour looks like the lung of an embryo in the early weeks of development. It contains two kinds of cancerous tissue mixed together: gland-forming epithelial cells and an immature, sarcoma-like supporting tissue (stroma). Because it has these two parts, it is called biphasic.
Adult pulmonary blastoma is a different disease from pleuropulmonary blastoma, a childhood lung tumour that is usually linked with an inherited DICER1 gene variant. In current classifications, adult pulmonary blastoma is grouped with the sarcomatoid carcinomas, a family of uncommon non-small cell lung cancers.
The tumour is usually found as a single large mass in the outer part of the lung. Many people have no symptoms when it is discovered; others develop a cough, chest pain, breathlessness or coughing up blood. In a classic series of 52 patients, the age of onset peaked in the fourth decade of life, and men and women were affected in similar numbers (Koss, Hochholzer and O’Leary, 1991).
Recent research has shown that most pulmonary blastomas carry acquired DICER1 mutations in the tumour, often together with changes in the beta-catenin (CTNNB1) gene (Alirezaie et al., 2024). Surgery is the main treatment, sometimes with chemotherapy and radiotherapy.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Biphasic lung cancer with embryonal-looking glands and immature stroma |
| Group | Sarcomatoid carcinoma, a rare type of non-small cell lung cancer |
| How common | Very rare; well under 1% of lung cancers |
| Typical age | Adults, with a wide range; often 30s to 60s |
| Sex | Men and women affected in similar numbers |
| Key gene changes | Acquired DICER1 and CTNNB1 (beta-catenin) mutations |
| Main treatment | Surgical removal, sometimes with chemotherapy and radiotherapy |
| Outlook | Variable; about 6 in 10 alive at 5 years in a US registry |
2. Types and related tumours
| Tumour | Description | Notes |
|---|---|---|
| Biphasic pulmonary blastoma | Malignant fetal-type glands plus immature stroma | The true “pulmonary blastoma” in current classifications |
| Well-differentiated fetal adenocarcinoma | Fetal-type glands only, without malignant stroma | Previously grouped with blastoma; now a type of adenocarcinoma with a better outlook |
| Pleuropulmonary blastoma | A childhood tumour, often cystic | Linked with inherited DICER1 variants; a separate disease |
In the series by Koss and colleagues, deaths from the disease were much less frequent with the gland-only type than with the biphasic type (Koss, Hochholzer and O’Leary, 1991).
How it compares with common lung cancers
| Feature | Pulmonary blastoma | Common non-small cell lung cancer |
|---|---|---|
| Typical age | Often younger adults | Usually over 65 |
| Tissue | Glands plus immature stroma | Glands (adenocarcinoma) or squamous cells |
| Position | Often a large peripheral mass | Anywhere in the lung |
| Key genes | DICER1, CTNNB1, TP53 | EGFR, KRAS, ALK, TP53 and others |
| Targeted drugs | None established | Available for many tumours |
3. Causes and risk factors
The cause is not known.
| Factor | Notes |
|---|---|
| Smoking | Many adults with pulmonary blastoma have a history of smoking |
| Acquired DICER1 mutations | Found in the tumour cells of most cases; usually not inherited |
| Beta-catenin (CTNNB1) mutations | Common, especially in tumours with small nodular cell clusters called morules |
| TP53 mutations | Seen in about half of tumours in one study |
Gene studies found somatic DICER1 changes in nearly all pulmonary blastomas examined, and their DNA methylation pattern resembled that of other DICER1-related tumours rather than ordinary lung cancers (Alirezaie et al., 2024). Because a small number of people with any DICER1-related tumour carry an inherited variant, genetic counselling may be offered, particularly to younger patients.
Understanding DICER1 and beta-catenin
| Gene | Normal role | What goes wrong |
|---|---|---|
| DICER1 | Makes small RNA molecules that switch other genes on and off during development | Mutations distort these signals, keeping cells in an immature, embryo-like state |
| CTNNB1 (beta-catenin) | Part of the Wnt signalling pathway, which controls cell growth and how cells stick together | Mutations let beta-catenin build up in the nucleus and drive growth; linked to morules |
| TP53 | A “guardian” gene that stops damaged cells from dividing | Loss allows abnormal cells to survive and multiply |
These findings explain why pulmonary blastoma looks like fetal lung tissue. They may also point to future targeted treatments.
Inherited DICER1 syndrome
DICER1 tumour predisposition syndrome is an inherited condition that raises the risk of pleuropulmonary blastoma in children, certain thyroid and ovarian tumours, and other rare cancers. In adult pulmonary blastoma the DICER1 changes are usually found only in the tumour. Even so, a specialist may suggest a blood test, especially if you are young or have a personal or family history of related tumours.
4. How does it look
On chest X-ray and CT
| Feature | Description |
|---|---|
| Number | Usually a single mass |
| Position | Often in the outer (peripheral) lung; no favoured lobe |
| Size | Often large, sometimes over 10 cm |
| Edge | Usually well defined |
| Inside | May contain areas of dead tissue or bleeding |
| Fluid | A pleural effusion may be present with larger tumours |
Under the microscope
| Feature | Description |
|---|---|
| Glands | Tubules lined by glycogen-rich cells resembling the fetal lung |
| Morules | Small solid nests of cells within the glands |
| Stroma | Immature, densely cellular, primitive-looking tissue |
| Other elements | Occasionally cartilage, muscle or bone-like areas |
| Stains | Epithelium positive for keratin and TTF-1; stroma positive for vimentin; abnormal nuclear beta-catenin |
The abnormal beta-catenin staining pattern, linked with the presence of morules, helps confirm the diagnosis (Sekine et al., 2003).
5. Symptoms
Common symptoms
- Cough that does not go away
- Chest pain
- Coughing up blood (haemoptysis)
- Breathlessness
Up to four in ten people have no symptoms, and the tumour is found on a chest X-ray done for another reason (Koss, Hochholzer and O’Leary, 1991).
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Fever or chest infection | Blockage of an airway |
| Weight loss and tiredness | Advanced disease |
| Fluid around the lung | Pleural spread |
| Bone pain or headaches | Rarely, spread to bones or brain |
| Bleeding into the chest | Rare complication of a large tumour |
When to seek medical advice
See a doctor if you have a cough lasting more than three weeks, coughing up blood, chest pain or unexplained breathlessness, whatever your age.
6. Diagnosis
| Test | Purpose |
|---|---|
| Chest X-ray | Often the first test |
| CT of the chest and abdomen | Shows size, position and spread |
| PET-CT | Looks for spread elsewhere |
| CT-guided needle biopsy | Samples a peripheral mass |
| Bronchoscopy | For central tumours or airway blockage |
| MRI of the brain | For staging in selected cases |
| Lung function tests | Check fitness for surgery |
| Molecular testing | DICER1 and CTNNB1; standard lung cancer markers are also often checked |
A small needle biopsy may show only one of the two components, so the full diagnosis is often made after the tumour is removed.
Why the diagnosis can be difficult
Pulmonary blastoma is so rare that most pathologists see only a few cases in their career. A needle biopsy may contain only glands, which can look like adenocarcinoma, or only stroma, which can look like a sarcoma. A review by a specialist thoracic pathologist, special stains and molecular tests help to reach the right diagnosis.
Staging
Pulmonary blastoma is staged using the TNM system for lung cancer.
| Stage | General meaning |
|---|---|
| Stage I-II | Confined to the lung, with or without nearby lymph nodes |
| Stage III | Spread to lymph nodes in the centre of the chest or nearby structures |
| Stage IV | Spread to the other lung, pleura or distant organs |
7. Treatment
Surgery
Complete surgical removal is the most effective treatment. In a US population study, people who did not have surgery had a higher risk of death (Bu et al., 2020).
| Operation | Description |
|---|---|
| Lobectomy | Removal of the affected lobe; the usual operation |
| Pneumonectomy | Removal of the whole lung for central or very large tumours |
| Lymph node dissection | Removes and checks chest lymph nodes |
| Minimally invasive (keyhole) surgery | Possible for some tumours |
Chemotherapy
| Situation | Approach |
|---|---|
| After surgery | Platinum-based chemotherapy is often considered, especially for larger or node-positive tumours |
| Before surgery | Sometimes used to shrink a large tumour |
| Advanced disease | Cisplatin or carboplatin combinations, for example with etoposide or ifosfamide |
Evidence comes mainly from case reports and small series, so treatment is tailored to each person.
Radiotherapy
Radiotherapy may be used after surgery with involved margins, for tumours that cannot be removed, or to relieve symptoms from spread to the bones or brain.
Newer treatments
Immunotherapy has been tried in some sarcomatoid lung cancers. For pulmonary blastoma specifically, there is little data. Clinical trials should be considered.
Side effects
| Treatment | Possible side effects |
|---|---|
| Lung surgery | Pain, breathlessness, air leak, chest infection |
| Chemotherapy | Tiredness, nausea, hair loss, infection risk, kidney and hearing effects with cisplatin |
| Radiotherapy | Tiredness, sore throat or swallowing, cough, skin changes |
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Before surgery | Breathing tests, heart checks and advice to stop smoking |
| Hospital stay | Usually 3-7 days after a lobectomy |
| Recovery | 6-12 weeks to regain energy; breathing exercises and walking help |
| Chemotherapy | Usually 4 cycles, each lasting 3 weeks |
8. Outlook (prognosis)
| Measure | Reported result |
|---|---|
| Median survival in a US registry | About 9 years (Bu et al., 2020) |
| 5-year survival | About 58% |
| 10-year survival | About 49% |
| Deaths from biphasic tumours in a classic series | About half (Koss, Hochholzer and O’Leary, 1991) |
| Factor | Effect on outlook |
|---|---|
| Complete surgical removal | Better survival |
| Older age | Higher risk of death |
| Spread beyond the lung | Poorer outlook |
| Tumour 5 cm or larger | Poorer outlook for biphasic tumours |
| Recurrence after treatment | The strongest sign of poor prognosis in biphasic tumours |
| Biphasic rather than gland-only type | Poorer outlook |
9. Follow-up
| Follow-up | Purpose |
|---|---|
| CT scan every 3-6 months for the first 2 years | Looks for recurrence |
| Then every 6-12 months up to 5 years | Continued monitoring |
| Lung function and breathing review | After surgery |
| Symptom checks | New cough, pain, headaches or bone pain |
| Genetic counselling | If an inherited DICER1 variant is suspected |
10. Living with pulmonary blastoma
- Stop smoking, which helps recovery and lowers the risk of other cancers
- Do breathing exercises and keep walking to rebuild lung capacity
- Join pulmonary rehabilitation if breathlessness persists
- Have flu and pneumonia vaccinations as advised
- Report new symptoms promptly between scans
- Seek support from lung cancer charities and rare cancer networks
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as pleuropulmonary blastoma? | No; that is a childhood tumour with different genetics and treatment |
| Is it a type of lung cancer? | Yes, a rare sarcomatoid non-small cell lung cancer |
| Is it inherited? | Usually not; DICER1 changes are usually acquired in the tumour |
| Can it be cured? | Yes, especially when completely removed at an early stage |
| Will I need chemotherapy? | Often, depending on the stage and how completely the tumour was removed |
| Are targeted drugs available? | Not yet specifically; research into DICER1 and beta-catenin pathways is ongoing |
| Why does it affect younger people? | The reason is unclear, but it often occurs earlier than ordinary lung cancer |
| Will I be able to breathe normally after surgery? | Most people adapt well after a lobectomy, though strenuous exercise may feel harder |
12. Questions to ask your care team
- Is my tumour biphasic pulmonary blastoma or fetal adenocarcinoma?
- What is the stage, and can it be completely removed?
- Do I need chemotherapy or radiotherapy after surgery?
- Should I have DICER1 testing or genetic counselling?
- Are there clinical trials for rare lung cancers I could join?
- How often will I have CT scans?
- Has my biopsy been reviewed by a specialist lung pathologist?
Resources
- Alirezaie, N. et al. (2024) ‘Exomic and epigenomic analysis of pulmonary blastoma’, Lung Cancer, 195, 107916.
- Bu, X. et al. (2020) ‘Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis’, BMC Cancer, 20(1), 811.
- Koss, M.N., Hochholzer, L. and O’Leary, T. (1991) ‘Pulmonary blastomas’, Cancer, 67(9), pp. 2368-2381.
- Sekine, S. et al. (2003) ‘Beta-catenin mutations in pulmonary blastomas: association with morule formation’, Journal of Pathology, 200(2), pp. 214-221.
- National Cancer Institute (2026) Non-Small Cell Lung Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.